- Home
- OCX vs CRIS Comparison
OCX vs CRIS Comparison
Compare OCX & CRIS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OCX
- CRIS
- Stock Information
- Founded
- OCX 2009
- CRIS 2000
- Country
- OCX United States
- CRIS United States
- Employees
- OCX N/A
- CRIS N/A
- Industry
- OCX Biotechnology: In Vitro & In Vivo Diagnostic Substances
- CRIS Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- OCX Health Care
- CRIS Health Care
- Exchange
- OCX Nasdaq
- CRIS Nasdaq
- Market Cap
- OCX 38.7M
- CRIS 31.2M
- IPO Year
- OCX N/A
- CRIS 2000
- Fundamental
- Price
- OCX $2.20
- CRIS $3.22
- Analyst Decision
- OCX Buy
- CRIS Strong Buy
- Analyst Count
- OCX 3
- CRIS 3
- Target Price
- OCX $4.42
- CRIS $23.00
- AVG Volume (30 Days)
- OCX 112.4K
- CRIS 67.7K
- Earning Date
- OCX 11-12-2024
- CRIS 02-06-2025
- Dividend Yield
- OCX N/A
- CRIS N/A
- EPS Growth
- OCX N/A
- CRIS N/A
- EPS
- OCX N/A
- CRIS N/A
- Revenue
- OCX $709,000.00
- CRIS $10,259,000.00
- Revenue This Year
- OCX N/A
- CRIS N/A
- Revenue Next Year
- OCX $106.34
- CRIS N/A
- P/E Ratio
- OCX N/A
- CRIS N/A
- Revenue Growth
- OCX N/A
- CRIS 0.44
- 52 Week Low
- OCX $1.98
- CRIS $3.22
- 52 Week High
- OCX $3.82
- CRIS $17.49
- Technical
- Relative Strength Index (RSI)
- OCX 29.70
- CRIS 29.11
- Support Level
- OCX $2.33
- CRIS $3.75
- Resistance Level
- OCX $2.48
- CRIS $4.25
- Average True Range (ATR)
- OCX 0.16
- CRIS 0.33
- MACD
- OCX -0.01
- CRIS -0.06
- Stochastic Oscillator
- OCX 39.29
- CRIS 0.00
About OCX Oncocyte Corporation
OncoCyte Corp focuses on the discovery, development, and commercialization of novel, non-invasive, liquid biopsy diagnostics for the early detection of cancer. The company develops diagnostic tests based on liquid biopsies using blood or urine samples for detecting lung, bladder, and breast cancers. In addition, it also develops screening diagnostics as potential replacements for screening imaging procedures that do not meet the needs of patients, health care providers or payers.
About CRIS Curis Inc.
Curis Inc is a biotechnology company that develops and commercializes innovative drugs and therapies in the immuno-oncology and precision oncology therapeutic areas. The company targets solid tumors, diffuse large B-cell lymphoma, advanced solid tumors or lymphomas, hematological cancers, and others. Its pipeline products include Fimepinostat, CA-170, CA-4948, CA-327, and Erivedge.